ASCO 2023 | SUCCESSOR-2 rationale: mezigdomide in combination with carfilzomib & dexamethasone for R/R myeloma
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, provides an update on the ongoing Phase III SUCCESSOR-2 trial (NCT05552976) assessing mezigdomide in combination with carfilzomib and dexamethasone (Kd) for relapsed/refractory (R/R) multiple myeloma. Dr Cerchione highlights the study’s rationale and the potential of this combination as a second-line treatment, especially for patients with a suboptimal response to frontline daratumumab-based regimens. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
